Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108856883> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2108856883 endingPage "6" @default.
- W2108856883 startingPage "1321" @default.
- W2108856883 abstract "Topoisomerase (Topo) IIalpha has proven to be an adequate anticancer target for tumors expressing this enzyme. In this study, we elucidated the effect of 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469; a new Topo IIbeta inhibitor) in the modulation of Topo IIalpha levels and sensitivity to Topo IIalpha poisons. We demonstrate by Western blot analysis that indolent B-cell tumors express undetectable levels of this enzyme and are refractory to the effects of Topo IIalpha poisons such as VP16. Using the Waldenstrom's macroglobulinemia (WM) cell line WSU-WM, we show that XK469 induced the expression of Topo IIalpha protein by 24 h compared with control. Immunofluorescence studies by confocal microscopy using a specific monoclonal antibody against Topo IIalpha supported the immunoblot findings with high intensity staining in XK469-exposed cells. To determine the effect of up-regulating Topo IIalpha on sensitivity of Topo IIalpha-directed inhibitors, WSU-WM cells were exposed to simultaneous, sequential, and reverse order XK469 and VP16. We demonstrate that 24 h of exposure to XK469 before VP16 resulted in a maximum synergistic response. In contrast, simultaneous or reverse order exposure resulted in an antagonistic effect. A similar trend was observed with cells obtained from chronic lymphocytic leukemia patients, but not in normal lymphocytes. This increase in VP16 sensitivity after 24 h of XK469 exposure was associated with VP16-dependent DNA cleavage, as demonstrated by formation of a smeared DNA band in a SDS-KCL DNA cleavage assay. From this study, we concluded that XK469 up-regulates Topo IIalpha levels and consequently sensitizes indolent malignant B cells to the cytotoxic effect of VP16 in a schedule-dependent manner." @default.
- W2108856883 created "2016-06-24" @default.
- W2108856883 creator A5007117793 @default.
- W2108856883 creator A5009731345 @default.
- W2108856883 creator A5011312785 @default.
- W2108856883 creator A5065296584 @default.
- W2108856883 creator A5075777714 @default.
- W2108856883 date "2002-12-01" @default.
- W2108856883 modified "2023-10-18" @default.
- W2108856883 title "2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity." @default.
- W2108856883 cites W1555002034 @default.
- W2108856883 cites W1579234620 @default.
- W2108856883 cites W1888632689 @default.
- W2108856883 cites W1972227366 @default.
- W2108856883 cites W1978719206 @default.
- W2108856883 cites W1990712342 @default.
- W2108856883 cites W2013706422 @default.
- W2108856883 cites W2029389235 @default.
- W2108856883 cites W2029533612 @default.
- W2108856883 cites W2030295874 @default.
- W2108856883 cites W2032937425 @default.
- W2108856883 cites W2064670731 @default.
- W2108856883 cites W2092975253 @default.
- W2108856883 cites W2094747148 @default.
- W2108856883 cites W2099649432 @default.
- W2108856883 cites W2123374199 @default.
- W2108856883 cites W2128297167 @default.
- W2108856883 cites W2137637658 @default.
- W2108856883 cites W2156524692 @default.
- W2108856883 cites W2187988269 @default.
- W2108856883 cites W2396328971 @default.
- W2108856883 cites W2404342288 @default.
- W2108856883 cites W2411906311 @default.
- W2108856883 cites W2419237537 @default.
- W2108856883 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12516965" @default.
- W2108856883 hasPublicationYear "2002" @default.
- W2108856883 type Work @default.
- W2108856883 sameAs 2108856883 @default.
- W2108856883 citedByCount "2" @default.
- W2108856883 crossrefType "journal-article" @default.
- W2108856883 hasAuthorship W2108856883A5007117793 @default.
- W2108856883 hasAuthorship W2108856883A5009731345 @default.
- W2108856883 hasAuthorship W2108856883A5011312785 @default.
- W2108856883 hasAuthorship W2108856883A5065296584 @default.
- W2108856883 hasAuthorship W2108856883A5075777714 @default.
- W2108856883 hasConcept C109316439 @default.
- W2108856883 hasConcept C147897179 @default.
- W2108856883 hasConcept C153911025 @default.
- W2108856883 hasConcept C181199279 @default.
- W2108856883 hasConcept C202751555 @default.
- W2108856883 hasConcept C2780500152 @default.
- W2108856883 hasConcept C55493867 @default.
- W2108856883 hasConcept C86803240 @default.
- W2108856883 hasConceptScore W2108856883C109316439 @default.
- W2108856883 hasConceptScore W2108856883C147897179 @default.
- W2108856883 hasConceptScore W2108856883C153911025 @default.
- W2108856883 hasConceptScore W2108856883C181199279 @default.
- W2108856883 hasConceptScore W2108856883C202751555 @default.
- W2108856883 hasConceptScore W2108856883C2780500152 @default.
- W2108856883 hasConceptScore W2108856883C55493867 @default.
- W2108856883 hasConceptScore W2108856883C86803240 @default.
- W2108856883 hasIssue "14" @default.
- W2108856883 hasLocation W21088568831 @default.
- W2108856883 hasOpenAccess W2108856883 @default.
- W2108856883 hasPrimaryLocation W21088568831 @default.
- W2108856883 hasRelatedWork W1973502067 @default.
- W2108856883 hasRelatedWork W2031714750 @default.
- W2108856883 hasRelatedWork W2044150722 @default.
- W2108856883 hasRelatedWork W2348672416 @default.
- W2108856883 hasRelatedWork W2354948779 @default.
- W2108856883 hasRelatedWork W2387801567 @default.
- W2108856883 hasRelatedWork W2388800266 @default.
- W2108856883 hasRelatedWork W2409509945 @default.
- W2108856883 hasRelatedWork W2793138419 @default.
- W2108856883 hasRelatedWork W3146664673 @default.
- W2108856883 hasVolume "1" @default.
- W2108856883 isParatext "false" @default.
- W2108856883 isRetracted "false" @default.
- W2108856883 magId "2108856883" @default.
- W2108856883 workType "article" @default.